Aethlon Medical (AEMD) Expected to Release Earnings on Wednesday

Aethlon Medical (NASDAQ:AEMD) is expected to be posting its Q1 2027 results before the market opens on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.7850) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Aethlon Medical Trading Up 5.6%

Shares of NASDAQ:AEMD opened at $3.52 on Wednesday. The stock has a 50 day moving average of $6.24 and a 200 day moving average of $9.38. The company has a market cap of $11.44 million, a PE ratio of -0.24 and a beta of 1.41. Aethlon Medical has a 12-month low of $2.62 and a 12-month high of $137.00.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Aethlon Medical presently has an average rating of “Reduce”.

Institutional Investors Weigh In On Aethlon Medical

A hedge fund recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical?stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life?threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.